NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.398) was uploaded to the NHS England Website on Tuesday 19, May 2026.
The following changes have been introduced:
Lisocabtagene maraleucel (LIS02a)
For treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS02b) can only be completed as a continuation of this first part of the form (LIS02a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel.
Recommended for routine commissioning, receiving CDF interim funding
Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)
Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Moved into routine commissioning - section B of list